Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases
J Xi, R Zhuang, L Kong, R He, H Zhu… - European Journal of …, 2019 - Elsevier
The immunoproteasome, a specialized form of proteasome, is mainly expressed in
lymphocytes and monocytes of jawed vertebrates and responsible for the generation of …
lymphocytes and monocytes of jawed vertebrates and responsible for the generation of …
Inhibitors of the immunoproteasome: current status and future directions
The ubiquitin-proteasome system (UPS) plays a vital role in maintaining protein
homeostasis and regulating numerous cellular processes. The proteasome, a multi-protease …
homeostasis and regulating numerous cellular processes. The proteasome, a multi-protease …
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases
The immunoproteasome is predominantly expressed in monocytes and lymphocytes and is
responsible for the generation of antigenic peptides for cell-mediated immunity. Upon the …
responsible for the generation of antigenic peptides for cell-mediated immunity. Upon the …
Immunoproteasome-selective inhibitors: the future of autoimmune diseases?
C Zhang, H Zhu, J Shao, R He, J Xi… - Future Medicinal …, 2020 - Taylor & Francis
The immunoproteasome, a specialized variant of the constitutive one, is predominantly
expressed in lymphocytes and monocytes of jawed vertebrates and is considered to be …
expressed in lymphocytes and monocytes of jawed vertebrates and is considered to be …
Design and evaluation of highly selective human immunoproteasome inhibitors reveal a compensatory process that preserves immune cell viability
E Ladi, C Everett, CE Stivala, BE Daniels… - Journal of Medicinal …, 2019 - ACS Publications
The pan-proteasome inhibitor bortezomib demonstrated clinical efficacy in off-label trials of
Systemic Lupus Erythematosus. One potential mechanism of this clinical benefit is from the …
Systemic Lupus Erythematosus. One potential mechanism of this clinical benefit is from the …
Development of novel amides as noncovalent inhibitors of immunoproteasomes
The development of immunoproteasome‐selective inhibitors is a promising strategy for
treating hematologic malignancies, autoimmune and inflammatory diseases. In this context …
treating hematologic malignancies, autoimmune and inflammatory diseases. In this context …
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma
R Ettari, M Zappalà, S Grasso, C Musolino… - Pharmacology & …, 2018 - Elsevier
The ubiquitin-proteasome system (UPS) is the major non-lysosomal proteolytic system for
the degradation of abnormal or damaged proteins no longer required. The proteasome is …
the degradation of abnormal or damaged proteins no longer required. The proteasome is …
Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome
Background and Purpose Multicatalytic endopeptidase complex‐like‐1 (β2i), low molecular
mass polypeptide (LMP) 2 (β1i) and LMP7 (β5i) are the proteolytically active subunits of the …
mass polypeptide (LMP) 2 (β1i) and LMP7 (β5i) are the proteolytically active subunits of the …
The immunoproteasome: an emerging therapeutic target
The proteasome, a large multisubunit protease complex, has been extensively investigated
over the years, greatly enhancing our understanding of critical roles that the proteasome …
over the years, greatly enhancing our understanding of critical roles that the proteasome …
Discovery and early clinical development of selective immunoproteasome inhibitors
CJ Kirk, T Muchamuel, J Wang, RA Fan - Cells, 2021 - mdpi.com
Inhibitors of the proteolytic activity of the 20S proteasome have transformed the treatment of
multiple B-cell malignancies. These agents have also been employed with success in the …
multiple B-cell malignancies. These agents have also been employed with success in the …
相关搜索
- immunoproteasome selective inhibitors
- hematologic malignancies autoimmune diseases
- selective inhibitors promising strategy
- immunoproteasome inhibitors cell viability
- immunoproteasome inhibitors design and evaluation
- immunoproteasome inhibitors compensatory process
- hematologic malignancies promising strategy